Johnson & Johnson announced plans to present new data regarding its treatment IMAAVY across 15 novel abstracts at two upcoming medical conferences. The presentations will cover the treatment of Generalized Myasthenia Gravis (GMG) and are scheduled for the 2026 MGFA Scientific Session and the AANEM Annual Meeting.
The company will utilize the conferences to share findings related to the efficacy and safety profile of IMAAVY in patients with GMG. The specific dates for the MGFA Scientific Session and the AANEM Annual Meeting were not provided in the filing.
